Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The goal of this proposal is to develop a more effective and better tolerated regimen.
Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
John Reagan Ryan Stevenson
Collaborators:
Memorial Hospital of Rhode Island Rhode Island Hospital The Miriam Hospital